通过抑制CDK4/6和HIF2α在默克尔细胞癌中增强免疫反应
Jung Hyun Lee1,2, Justin Daho Lee2, Kelly Paulson1,3,4
1Department of Dermatology, School of Medicine, University of Washington, Seattle, WA, USA.
Heliyon
|January 4, 2024
概括
这项研究表明,将CDK4/6抑制剂与HIF2α抑制相结合,可以增强梅克尔细胞癌 (MCC) 的癌细胞死亡. 这种方法增加了免疫细胞死亡,为MCC免疫疗法提供了一个有前途的新途径.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 分子生物学分子生物学
背景情况:
- 默克尔细胞癌 (MCC) 是一种具有有限治疗选择的侵袭性皮肤癌.
- 虽然PD-1免疫疗法最初显示出有效性,但复发率仍然很高,需要新的治疗策略.
- 循环素依赖性激酶4和6 (CDK4/6) 是细胞循环的关键调节者,在癌症治疗中发挥着新兴的作用.
研究的目的:
- 研究CDK4/6抑制剂与HIF2α抑制结合用于治疗MCC的潜力.
- 探索Palbociclib和HIF2α抑制影响MCC.中的PD-L1表达和细胞死亡的机制.
- 评估这种综合策略对活性氧物种 (ROS) 水平,铁亡和整体免疫细胞死亡的影响.
主要方法:
- 在MCC细胞系中利用了CDK4/6抑制剂palbociclib和HIF2α抑制剂TC-S7009.
- 评估PD-L1基因转录和表面表达.
- 测量了活性氧物种 (ROS) 含量和SLC7A11表达.
- 量化细胞死亡,专注于铁亡诱导.
主要成果:
- 帕尔博西基利布治疗通过HIF2α激活增加了MCC细胞中的PD-L1表达.
- 通过TC-S7009抑制HIF2α抵消了palbociclib诱导的PD-L1上调和增强细胞死亡.
- 同时准CDK4/6和HIF2α提高了ROS水平,并抑制了SLC7A11,促进了铁亡.
- 组合疗法显著增加了各种MCC细胞系的免疫细胞死亡.
结论:
- 对CDK4/6和HIF2α的双抑制是克服MCC免疫疗法耐药性的有希望的策略.
- 这种方法增强了铁和其他形式的免疫细胞死亡,可能改善治疗结果.
- 对这种组合疗法的进一步研究可以促进MCC治疗和癌症免疫治疗.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


